Frazier Healthcare Partners, a Seattle, Wash.- and Menlo Park, CA-based healthcare-focused investment firm, closed its fund VIII, at $262m.
As the firm’s first sector-specific fund, Frazier Life Sciences VIII will invest exclusively in companies (in the United States, Canada and Europe) advancing novel therapeutics across the spectrum of drug development ranging from early-stage, preclinical opportunities, to later-stage clinical development activities and specialty pharmaceutical companies,
Company formation will remain a core strategy.
Founded in 1991 and led by managing general partners Jamie Topper and Patrick Heron, Frazier Life Sciences has total committed capital under management of more than $2.4 billion. Recent firm’s IPOs and exits include Calibrium (acquired by Novo Nordisk), ProNAi (IPO: DNAi), Collegium (IPO: COLL), Cidara (IPO: CDTX), Tobira (merged with Regado), PreCision Dermatology (acquired by Valeant), Rempex (acquired by The Medicines Company) and Incline (acquired by The Medicines Company). In addition, over 14 approved therapeutics have originated from Frazier Life Sciences-backed companies since 2010, including treatments for hematologic cancers (Zydelig), drug-resistant bacterial infections (Zerbaxa, Teflaro) and pain (Ofirmev, Ionsys).